European Journal of Biomedical and Pharmaceutical Sciences

BODY COMPOSITION CHANGES ARE NOT ASSOCIATED WITH INFLAMMATORY AND METABOLIC MARKERS IN PATIENTS WITH ADVANCED PROSTATE CANCER MANAGED WITH ANDROGEN DEPRIVATION THERAPY

*Carlos V. Serrano, Cicero P. de Albuquerque, Rafael Coelho, Heraldo P. de Souza, Denise F. Barbeiro, James de Lemos, William C. Nahas, Miguel Srougi, José Antonio F. Ramires and Roberto Kalil-Filho

ABSTRACT

Background: The primary treatment of advanced prostate cancer is based on pharmacological or surgical androgen-deprivation therapy (ADT). Inhibition of testosterone production that interrupts testosterone-induced growth of the prostate tumor has several undesirable effects on the metabolic profile. However, these effects are not completely understood. The purpose of this study was to evaluate the changes in body composition and inflammatory / metabolic profile in men managed with ADT for advanced prostate cancer. Methods: In this prospective study, 17 patients (77.56.74 years) with advanced prostate cancer underwent pharmacological or surgical ADT. Clinical, body composition, inflammatory and metabolic parameters were determined before and after 6 months of surgery. Results: All patients presented significant decreases in testosterone (p=0.001) and PSA (p<0.001) levels after ADT. Body composition parameters increased markedly: weight (71.512.8 to 74.713.5 kg, p<0.001), body mass index (25.73.3 to 26.93.3 kg/m2, p<0.001) and waist circumference (96.511.3 to 99.510.1 cm, p=0.004). Marked changes were noted on blood levels of insulin (9.43.1 to 12.64.1 mU/L, p<0.001) and leptin (6022.05928.4 to 9612.16279.0 pg/mL, p=0.017). However, inflammatory (fibrinogen, C-reactive protein, interleukin-6, tumor necrosis factor alpha, monocyte chemoattractant protein-1, intercellular adhesion molecule-1, vascular adhesion molecule-1 and adiponectin) and metabolic (glycemic and lipid profiles) markers did not present significant variations. Conclusions: These data demonstrate that, among men with advanced prostate cancer treated by ADT, the marked changes in body composition after 6 months did not reflect changes in inflammatory and metabolic markers. Thus, an association between ADT and inflammatory / metabolic markers is yet to be described.

Keywords: Prostate cancer, androgen-deprivation therapy, metabolic syndrome, inflammation.